Feedback Valuation
Is FDBK undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
1/6Valuation Score 1/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of FDBK when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate FDBK's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate FDBK's fair value for valuation analysis.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for FDBK?
Key metric: As FDBK is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.
| What is FDBK's PS Ratio? | |
|---|---|
| PS Ratio | 2.3x |
| Sales | UK£1.18m |
| Market Cap | UK£2.73m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | n/a |
| Enterprise Value/EBITDA | n/a |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does FDBK's PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 1.6x | ||
IQAI IQ-AI | 4.6x | n/a | UK£3.5m |
INHC Induction Healthcare Group | 0.7x | 13.0% | UK£8.4m |
DXSP DXS International | 0.3x | n/a | UK£992.3k |
COG Cambridge Cognition Holdings | 0.9x | 11.0% | UK£11.5m |
FDBK Feedback | 2.3x | 44.9% | UK£2.7m |
Price-To-Sales vs Peers: FDBK is expensive based on its Price-To-Sales Ratio (2.3x) compared to the peer average (1.6x).
Price to Sales Ratio vs Industry
How does FDBK's PS Ratio compare vs other companies in the European Healthcare Services Industry?
| 5 Companies | Price / Sales | Estimated Growth | Market Cap |
|---|---|---|---|
| 5 Companies | Estimated Growth | Market Cap | |
|---|---|---|---|
Price-To-Sales vs Industry: FDBK is expensive based on its Price-To-Sales Ratio (2.3x) compared to the European Healthcare Services industry average (2.2x).
Price to Sales Ratio vs Fair Ratio
What is FDBK's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 2.3x |
| Fair PS Ratio | 7.9x |
Price-To-Sales vs Fair Ratio: FDBK is good value based on its Price-To-Sales Ratio (2.3x) compared to the estimated Fair Price-To-Sales Ratio (7.9x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
Elevance Health
US$93.4b
Operates as a health benefits company in the United States.
0HG8
US$401.70
7D
-0.06%
1Y
-16.0%
Centene
US$30.5b
Operates as a healthcare enterprise that provides programs and services to under-insured and uninsured families, commercial organizations, and military families in the United States.
0HVB
US$60.47
7D
5.2%
1Y
-18.4%
Kooth
UK£60.0m
Provides digital mental health services to children, young people, and adults in the United Kingdom.
KOO
UK£1.65
7D
1.5%
1Y
-45.2%